Key result
POLARx cryoballoon matches Arctic Front Advance in procedure times and acute efficacy for PVI.
Why the study?
A new cryoballoon manufacturer received regulatory CE marking (POLARx), motivating an evaluation of early experience and procedural aspects compared to the incumbent Arctic Front Advance catheter.
Does POLARx cryoballoon ablation improve procedural metrics compared to Arctic Front Advance in patients with atrial fibrillation?
Observational (n=80)
No
Does POLARx cryoballoon ablation improve procedural metrics compared to Arctic Front Advance in patients with atrial fibrillation?
The POLARx cryoballoon is effective for pulmonary vein isolation with similar acute efficacy to the Arctic Front Advance, though with lower measured temperatures and slightly higher fluoroscopy and dwell times.
Answers are grounded in this paper and cite their sources.
Comparable acute PVI efficacy in this cohort; supports POLARx as alternative but leaves open randomized confirmation of outcomes.
INTRODUCTION: Cryoballoon ablation is an established technique to achieve pulmonary vein isolation in patients with atrial fibrillation (AF). Recently, a new manufacturer of cryoballoon achieved regulatory CE marking (POLARx™; Boston Scientific). We describe our early experience of using this new market entrant of the technology and describe procedural aspects in comparison to the incumbent Medtronic Arctic Front Advance™. METHODS: We assessed the first 40 AF ablations performed with the POLARx catheter at the Barts Heart Centre. These patients were compared with a contemporaneous series of patients undergoing ablation by the same operators using the Arctic Front Advance. Procedural metrics were prospectively recorded. RESULTS: A total of four operators undertook 40 cases using the POLARx catheter, compared with 40 cases using the Arctic Front Advance. Procedure times (60.0 vs. 60.0 min) were similar between the two technologies, however left atrial dwell time (35.0 vs 39.0 min) and fluoroscopy times (3.3 vs. 5.2 min) were higher with the POLARx. Measured nadir and isolation balloon temperatures were significantly lower with POLARx. Almost all veins were isolated with a median freezing time of 16.0 (POLARx) versus 15.0 (Arctic Front Advance) min. The rate of procedural complications was low in both groups. CONCLUSION: The POLARx cryoballoon is effective for pulmonary vein isolation. Measured isolation and nadir temperatures are lower compared with the predicate Arctic Front Advance catheter. The technology appears similar in acute efficacy and has a short learning curve, but formal dosing studies may be required to prove equivalence of efficacy.
No takes yet. Share an insight, caveat, or question.
Creta et al. (2021) conducted an observational in Atrial fibrillation (n=80). POLARx cryoballoon catheter vs. Arctic Front Advance cryoballoon catheter was evaluated on Procedure time (minutes). The POLARx cryoballoon demonstrated similar procedure times and acute efficacy for pulmonary vein isolation compared with the Arctic Front Advance catheter.
Synapse has enriched 10 related papers. Consider them for comparative context: